文献速递衰弱、肌少症与跌倒认知障碍与谵妄老年综合评估

临床前期阿尔茨海默病中衰弱患病率及其与认知的关联

Prevalence of frailty and its association with cognition in preclinical Alzheimer's disease: a cross-sectional analysis of baseline data from the A4 study.
PubMed 文献 · Age Ageing · 2026-01-01

结果显示,临床前期AD的衰弱患病率为22%(FI-CVR模型为44%),Aβ+者衰弱风险更高,衰弱者PACC评分更低,但衰弱不影响Aβ状态与认知的关系。

要点

  • 临床前期AD中衰弱患病率为22%,去除认知变量后升至44%。
  • Aβ+受试者比Aβ-者更易衰弱,两种FI模型校正后OR分别为1.43与1.21。
  • 衰弱者PACC评分更低,但衰弱不改变Aβ状态与认知的关联。

核心结论

  • 在临床前期AD试验筛选人群中,Aβ水平升高与衰弱相关,衰弱与认知表现下降相关且独立于Aβ水平。
  • 上述关联及衰弱是否独立于Aβ状态与纵向认知下降相关,尚需进一步研究。

研究设计与样本

  • 构建两种衰弱指数模型:FI-Full与去除认知变量的FI-CVR,衰弱定义为FI>0.25。
  • 分析按淀粉样蛋白状态分组的衰弱患病率,以及衰弱与PACC评分的关联,并校正年龄、性别和教育程度。
  • 评估衰弱是否调节淀粉样蛋白状态与认知之间的关系。

主要发现

  • 受试者平均年龄71.3±4.7岁,30%为Aβ+,59%为女性。
  • 临床前期AD的衰弱患病率为22%,去除认知变量后为44%。
  • 校正分析中Aβ+者比Aβ-者更易衰弱:FI-Full的OR为1.43(95%CI 1.20-1.71,P<.001),FI-CVR的OR为1.21(95%CI 1.05-1.40,P<.008)。
  • 衰弱者PACC评分平均更低:FI-Full为-0.58(95%CI -0.76至-0.40,P<.001),FI-CVR为-0.26(95%CI -0.40至-0.12,P<.001)。
  • 衰弱未影响Aβ状态与认知之间的关系。

关键数值与推荐

  • 衰弱判定阈值:FI>0.25。
  • Aβ+者衰弱风险:FI-Full OR 1.43(95%CI 1.20-1.71,P<.001)。
  • Aβ+者衰弱风险:FI-CVR OR 1.21(95%CI 1.05-1.40,P<.008)。
  • 衰弱者PACC评分差异:FI-Full -0.58(95%CI -0.76至-0.40,P<.001);FI-CVR -0.26(95%CI -0.40至-0.12,P<.001)。

临床怎么用

  • 在临床前期AD人群中评估衰弱时,应注意衰弱与认知表现下降相关且独立于Aβ状态。
  • FI模型是否纳入认知变量会明显影响衰弱患病率(22%对44%),解读时需说明所用模型。

局限性

  • 为横断面分析,无法判断衰弱与认知下降的纵向因果关系。
  • 研究人群为临床前期AD试验筛选人群,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prevalence and role of frailty in preclinical Alzheimer's disease (AD) is unclear. METHODS: Cross-sectional analyses of pre-randomization data from the Anti-Amyloid Treatment in Asymptomatic AD (A4) study were analysed to derive two models of a frailty index (FI)-full [FI-Full] and cognitive variables removed [FI-CVR]. The prevalence of frailty (FI > 0.25) according to amyloid status (Aβ+/-), and the association of frailty and cognition (determined by the Preclinical Alzheimer Cognitive Composite (PACC) score) and whether frailty moderates the relationship between amyloid status and cognition was assessed, adjusting for age, sex and education. RESULTS: Four thousand four hundred eighty-six participants were included (mean age 71.3 ± 4.7 years, 30% participants Aβ+, 59% female). The prevalence of frailty in preclinical AD was 22% (or 44% when cognitive variables were removed from the FI). Using either FI model, in adjusted analyses, Aβ+ participants were more likely to be frail compared to Aβ- [FI-Full-Odds ratio (OR) 1.43 95% confidence interval (CI) 1.20-1.71, P < .001; FI-CVR-OR 1.21 95% CI 1.05-1.40, P < .008]. Frail participants had lower PACC scores compared to non-frail participants, on average (FI-Full-PACC score -0.58 95% CI -0.76 to -0.40, P < .001; FI-CVR-PACC score -0.26 95% CI -0.40 to -0.12, P < .001). Frailty did not influence the relationship between Aβ status and cognition. CONCLUSIONS: In a cohort screened for a preclinical AD trial, elevated Aβ levels were associated with frailty and frailty was associated with reduced cognitive performance independent of elevated Aβ levels. These associations, and whether or not frailty is associated with longitudinal cognitive decline independent of Aβ status, warrant further study.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Huynh ALH, Wang S, Lee K, et al. Prevalence of frailty and its association with cognition in preclinical Alzheimer's disease: a cross-sectional analysis of baseline data from the A4 study. Age Ageing. 2026. PMID: 41569280. doi:10.1093/ageing/afaf378

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。